The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.
The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.
